TCGA-E9-A1R7-01A-11R-A14M-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 49
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.450
- MITOTIC_SPINDLE+0.320
- G2M_CHECKPOINT+0.270
- E2F_TARGETS+0.200
- MYC_TARGETS_V1+0.170
- UNFOLDED_PROTEIN_RESPONSE+0.170
- ANDROGEN_RESPONSE+0.150
- BILE_ACID_METABOLISM+0.150
- PEROXISOME+0.150
- HEME_METABOLISM+0.140
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.530
- TNFA_SIGNALING_VIA_NFKB-0.510
- CHOLESTEROL_HOMEOSTASIS-0.480
- INFLAMMATORY_RESPONSE-0.480
- INTERFERON_ALPHA_RESPONSE-0.480
- INTERFERON_GAMMA_RESPONSE-0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- IL6_JAK_STAT3_SIGNALING-0.440
- HYPOXIA-0.400
- APICAL_SURFACE-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3021 | Med | Medulloblastoma | 0.918 |
| 2 | 20040104.LumB | — | B | 0.887 |
| 3 | TCGA-E2-A15T-01A-11R-A115-07 | — | B | 0.885 |
| 4 | 8ca13509-abad-46b7-92f4-fa741bc52b42 | — | — | 0.885 |
| 5 | SRR661290 | GTEX | — | 0.882 |
| 6 | MDT-AP-3311 | Med | Medulloblastoma | 0.879 |
| 7 | TCGA-G2-A3VY-01A-11R-A22U-07 | — | — | 0.878 |
| 8 | SRR662871 | GTEX | — | 0.878 |
| 9 | SRR12202425 | — | — | 0.876 |
| 10 | MDT-AP-0113 | Med | Medulloblastoma | 0.873 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.450 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.270 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.170 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| PEROXISOME | 0.150 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.080 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.070 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.010 | Cobimetinib | — uncovered |